COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

C. Agrati; Cosimo S. Di; D. Fenoglio; G. Apolone; F. Ciceri; G. Ciliberto; F. Baldanti; M. Costantini; D. Giannarelli; G. Ippolito; Franco Locatelli; A. Mantovani; A. Morrone; F. Tagliavini; A. Uccelli; P. L. Zinzani; N. Silvestris; M. Rescigno

doi:10.3389/fimmu.2021.704110

COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

C. Agrati
, Cosimo S. Di
, D. Fenoglio
, G. Apolone
, F. Ciceri
, G. Ciliberto
, F. Baldanti
, M. Costantini
, D. Giannarelli
, G. Ippolito
, Franco Locatelli
, A. Mantovani
, A. Morrone
, F. Tagliavini
, A. Uccelli
, P. L. Zinzani
, N. Silvestris^*
, M. Rescigno

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.

Lingua originale	Inglese
pagine (da-a)	1-8
Numero di pagine	8
Rivista	Frontiers in Immunology
Volume	12
Numero di pubblicazione	12
DOI	https://doi.org/10.3389/fimmu.2021.704110
Stato di pubblicazione	Pubblicato - 2021

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

All Science Journal Classification (ASJC) codes

Immunologia e Allergia
Immunologia

Keywords

COVID-19
SARS-CoV-2
cancer
immunocompromised
myasthenia
vaccine

Accesso al documento

10.3389/fimmu.2021.704110

Altri file e collegamenti

Cita questo

Agrati, C., Di, C. S., Fenoglio, D., Apolone, G., Ciceri, F., Ciliberto, G., Baldanti, F., Costantini, M., Giannarelli, D., Ippolito, G., Locatelli, F., Mantovani, A., Morrone, A., Tagliavini, F., Uccelli, A., Zinzani, P. L., Silvestris, N., & Rescigno, M. (2021). COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial. Frontiers in Immunology, 12(12), 1-8. https://doi.org/10.3389/fimmu.2021.704110

@article{cf0f220957e24257bfe6b15569e762b1,

title = "COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial",

abstract = "Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.",

keywords = "COVID-19, SARS-CoV-2, cancer, immunocompromised, myasthenia, vaccine, COVID-19, SARS-CoV-2, cancer, immunocompromised, myasthenia, vaccine",

author = "C. Agrati and Di, \{Cosimo S.\} and D. Fenoglio and G. Apolone and F. Ciceri and G. Ciliberto and F. Baldanti and M. Costantini and D. Giannarelli and G. Ippolito and Franco Locatelli and A. Mantovani and A. Morrone and F. Tagliavini and A. Uccelli and Zinzani, \{P. L.\} and N. Silvestris and M. Rescigno",

year = "2021",

doi = "10.3389/fimmu.2021.704110",

language = "English",

volume = "12",

pages = "1--8",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

number = "12",

}

Agrati, C, Di, CS, Fenoglio, D, Apolone, G, Ciceri, F, Ciliberto, G, Baldanti, F, Costantini, M, Giannarelli, D, Ippolito, G, Locatelli, F, Mantovani, A, Morrone, A, Tagliavini, F, Uccelli, A, Zinzani, PL, Silvestris, N & Rescigno, M 2021, 'COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial', Frontiers in Immunology, vol. 12, n. 12, pagg. 1-8. https://doi.org/10.3389/fimmu.2021.704110

TY - JOUR

T1 - COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

AU - Agrati, C.

AU - Di, Cosimo S.

AU - Fenoglio, D.

AU - Apolone, G.

AU - Ciceri, F.

AU - Ciliberto, G.

AU - Baldanti, F.

AU - Costantini, M.

AU - Giannarelli, D.

AU - Ippolito, G.

AU - Locatelli, Franco

AU - Mantovani, A.

AU - Morrone, A.

AU - Tagliavini, F.

AU - Uccelli, A.

AU - Zinzani, P. L.

AU - Silvestris, N.

AU - Rescigno, M.

PY - 2021

Y1 - 2021

N2 - Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.

AB - Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.

KW - COVID-19

KW - SARS-CoV-2

KW - cancer

KW - immunocompromised

KW - myasthenia

KW - vaccine

KW - COVID-19

KW - SARS-CoV-2

KW - cancer

KW - immunocompromised

KW - myasthenia

KW - vaccine

UR - https://publicatt.unicatt.it/handle/10807/228529

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85113853035&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85113853035&origin=inward

U2 - 10.3389/fimmu.2021.704110

DO - 10.3389/fimmu.2021.704110

M3 - Article

SN - 1664-3224

VL - 12

SP - 1

EP - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

IS - 12

ER -

COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

Abstract

OSS delle Nazioni Unite

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo